262 related articles for article (PubMed ID: 12649200)
1. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.
Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
3. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
4. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway.
Nam SY; Amoscato AA; Lee YJ
Oncogene; 2002 Jan; 21(3):337-46. PubMed ID: 11821946
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
6. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS
Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254
[TBL] [Abstract][Full Text] [Related]
7. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
[TBL] [Abstract][Full Text] [Related]
10. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB; Bhardwaj U; Takada Y
Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
[TBL] [Abstract][Full Text] [Related]
11. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
12. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
Tong X; Li H
Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
[TBL] [Abstract][Full Text] [Related]
13. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells.
Lee TJ; Jang JH; Noh HJ; Park EJ; Choi KS; Kwon TK
J Cell Biochem; 2010 Apr; 109(5):885-95. PubMed ID: 20127709
[TBL] [Abstract][Full Text] [Related]
17. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
18. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation.
Cho YL; Lee KS; Lee SJ; Namkoong S; Kim YM; Lee H; Ha KS; Han JA; Kwon YG; Kim YM
Biochem Biophys Res Commun; 2005 Jan; 326(4):752-8. PubMed ID: 15607733
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
Munshi A; McDonnell TJ; Meyn RE
Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
[TBL] [Abstract][Full Text] [Related]
20. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]